 Today I have the pleasure and the privilege of interviewing Executive Vice President and CFO, Mr. Andre Gotten. How are you today Andre? I'm good, thank you. Normally we don't interview the CFO but you're also the Executive Vice President. Can you tell us a little bit about your role at Intel Genics Technologies? I work very closely with Dr. Zerbe. I have great respect for him and also for the rest of the team. Of course we're really excited to talk to you about your recent deal with Tidalafil. Can you tell us more about this? This deal is probably the best deal that we ever signed at Intel Genics and it will probably start generating revenue by mid-year 2018. For all of those out there who are new to Intel Genics, they have a very interesting business model. Andre, can you tell us a little bit more about this business model? Yeah, our business model consists of five sources of revenue. We basically get upfront payment, R&D milestones, sales milestones, royalty or profit split with our partner and finally manufacturing revenue. We get manufacturing revenue when we are at the commercial phase of the project. Based on your business model, can you tell us how that translates to revenue and what we might anticipate for 2017? Yes, 2017, most of our revenue will be coming from R&D revenue. This is the great thing about signing multiple partner, Kimo being one of them. Depending on where the project is at the moment of the signing, we will get more or less R&D revenue. In this case, we'll get more than less R&D revenue in 2017 because the projects are just starting. One of our investor Intel members sent me a question asking me why you guys are manufacturing your oral films and why you're not outsourcing this. Can you explain this to us? Yeah, I mean, very simple answer. We get the margin in house as opposed to giving the margin away to contract manufacturing. So that's the main reason. Also, what's very important to us is to keep our know-how, keep our trade secrets in-house. So by having our own plan and manufacturing the product, then we keep all our intellectual property in house. How many people do you employ? And can you tell us a little bit more about your manufacturing facility? We employ about close to 30 people in total. Most people are in R&D because this is our main expertise. And the manufacturing, in regards to the manufacturing facility, it is in the process of GMP approval and certification by L Canada so that we can start manufacturing commercial goods by late 2017. Well Andre, is there anything else you'd like to add about why we should get excited about Intel Genics? I mean, obviously you've been with Intel Genics. Can you give us any additional data? I think that I fully agree with you when you mentioned that we're undervalued. I think it's a very good entry point right now. There's a lot of things happening, a lot of exciting things. We've been doing a lot of partnership and more to come. And with that recent, you know, the Dalla Field license, we feel that, you know, for any new investor, it's really the right time to come in because I see this company going and growing, you know, quite a bit in the near future. Well, you said it best, Andre. And thank you so much for joining us today. Thank you very much.